Taylor Frigon Capital Management LLC Buys 89 Shares of Stryker Co. (NYSE:SYK)

Taylor Frigon Capital Management LLC raised its stake in Stryker Co. (NYSE:SYKGet Rating) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,611 shares of the medical technology company’s stock after purchasing an additional 89 shares during the quarter. Taylor Frigon Capital Management LLC’s holdings in Stryker were worth $1,136,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Hazlett Burt & Watson Inc. bought a new position in shares of Stryker during the 3rd quarter worth approximately $41,000. Total Clarity Wealth Management Inc. bought a new stake in Stryker in the 2nd quarter valued at $44,000. Charter Oak Capital Management LLC bought a new stake in Stryker in the 2nd quarter valued at $50,000. Webster Bank N. A. boosted its stake in Stryker by 123.2% in the 3rd quarter. Webster Bank N. A. now owns 250 shares of the medical technology company’s stock valued at $51,000 after purchasing an additional 138 shares during the period. Finally, Western Pacific Wealth Management LP boosted its stake in Stryker by 3,862.5% in the 3rd quarter. Western Pacific Wealth Management LP now owns 317 shares of the medical technology company’s stock valued at $64,000 after purchasing an additional 309 shares during the period. 77.10% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SYK has been the subject of several analyst reports. Barclays lifted their price objective on Stryker from $257.00 to $265.00 in a report on Wednesday, January 4th. Royal Bank of Canada raised Stryker from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $240.00 to $284.00 in a report on Monday, January 9th. Jefferies Financial Group initiated coverage on Stryker in a report on Wednesday, October 12th. They issued a “buy” rating and a $270.00 price objective for the company. Evercore ISI lifted their price objective on Stryker to $265.00 in a report on Tuesday, January 3rd. Finally, Morgan Stanley lifted their price objective on Stryker from $220.00 to $260.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $260.68.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 6,571 shares of the company’s stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total transaction of $1,693,280.99. Following the transaction, the vice president now directly owns 9,264 shares of the company’s stock, valued at approximately $2,387,240.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, VP M Kathryn Fink sold 6,571 shares of the company’s stock in a transaction that occurred on Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total transaction of $1,693,280.99. Following the transaction, the vice president now directly owns 9,264 shares of the company’s stock, valued at approximately $2,387,240.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Srikant M. Datar sold 300 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $212.36, for a total value of $63,708.00. Following the transaction, the director now directly owns 4,861 shares in the company, valued at $1,032,281.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 80,079 shares of company stock valued at $19,354,832. 6.50% of the stock is owned by company insiders.

Stryker Trading Down 2.5 %

Shares of Stryker stock traded down $6.44 on Wednesday, hitting $249.31. 259,973 shares of the company’s stock traded hands, compared to its average volume of 1,326,523. Stryker Co. has a one year low of $188.84 and a one year high of $279.28. The company has a debt-to-equity ratio of 0.77, a current ratio of 2.04 and a quick ratio of 1.19. The company has a fifty day moving average of $243.85 and a two-hundred day moving average of $223.70. The company has a market capitalization of $94.35 billion, a price-to-earnings ratio of 39.77, a price-to-earnings-growth ratio of 2.87 and a beta of 0.94.

Stryker (NYSE:SYKGet Rating) last announced its earnings results on Monday, October 31st. The medical technology company reported $2.12 EPS for the quarter, missing the consensus estimate of $2.24 by ($0.12). Stryker had a net margin of 13.69% and a return on equity of 22.27%. The business had revenue of $4.48 billion for the quarter, compared to the consensus estimate of $4.46 billion. During the same quarter in the previous year, the company earned $2.20 EPS. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. As a group, sell-side analysts expect that Stryker Co. will post 9.17 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 31st. Investors of record on Friday, December 30th will be given a dividend of $0.75 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.70. The ex-dividend date is Thursday, December 29th. This represents a $3.00 annualized dividend and a dividend yield of 1.20%. Stryker’s dividend payout ratio is presently 46.66%.

Stryker Company Profile

(Get Rating)

Stryker Corp. operates as a medical technology company. It operates through the following segments: Orthopaedics & Spine and MedSurg & Neurotechnology. The Orthopaedics & Spine segment provides implants for use in total joint replacements, such as hip, knee, and shoulder, and trauma and extremities surgeries.

Featured Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKGet Rating).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.